Daniel Samacá-Samacá, Laura Prieto-Pinto, Andrés Yepes Peréz, Carolina Valderrama, Fabián Hernández
{"title":"阿勒替尼治疗转移性alk阳性NSCLC:系统评价和网络荟萃分析。","authors":"Daniel Samacá-Samacá, Laura Prieto-Pinto, Andrés Yepes Peréz, Carolina Valderrama, Fabián Hernández","doi":"10.2217/lmt-2022-0018","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To compare the efficacy and safety of alectinib with other ALK inhibitors in treating patients with metastatic or locally advanced <i>ALK</i>-positive NSCLC.</p><p><strong>Methods: </strong>A systematic literature review was conducted up to November 2021. Network meta-analyses were performed using the frequentist method (random effects). GRADE evidence profile was conducted.</p><p><strong>Results: </strong>13 RCTs were selected. For overall survival, alectinib was found to reduce the risk of death compared with crizotinib. In progression-free survival, alectinib reduced the risk of death or progression compared with crizotinib and ceritinib. Subgroup analysis by brain metastasis at baseline showed the superiority of alectinib over crizotinib and a similar effect compared with second-and third-generation inhibitors. Alectinib showed a good safety profile compared with the other ALK inhibitors.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"12 2","pages":"LMT59"},"PeriodicalIF":0.9000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/ba/lmt-12-59.PMC10242442.pdf","citationCount":"0","resultStr":"{\"title\":\"Alectinib for treating patients with metastatic <i>ALK</i>-positive NSCLC: systematic review and network metanalysis.\",\"authors\":\"Daniel Samacá-Samacá, Laura Prieto-Pinto, Andrés Yepes Peréz, Carolina Valderrama, Fabián Hernández\",\"doi\":\"10.2217/lmt-2022-0018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To compare the efficacy and safety of alectinib with other ALK inhibitors in treating patients with metastatic or locally advanced <i>ALK</i>-positive NSCLC.</p><p><strong>Methods: </strong>A systematic literature review was conducted up to November 2021. Network meta-analyses were performed using the frequentist method (random effects). GRADE evidence profile was conducted.</p><p><strong>Results: </strong>13 RCTs were selected. For overall survival, alectinib was found to reduce the risk of death compared with crizotinib. In progression-free survival, alectinib reduced the risk of death or progression compared with crizotinib and ceritinib. Subgroup analysis by brain metastasis at baseline showed the superiority of alectinib over crizotinib and a similar effect compared with second-and third-generation inhibitors. Alectinib showed a good safety profile compared with the other ALK inhibitors.</p>\",\"PeriodicalId\":43551,\"journal\":{\"name\":\"Lung Cancer Management\",\"volume\":\"12 2\",\"pages\":\"LMT59\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/ba/lmt-12-59.PMC10242442.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/lmt-2022-0018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2022-0018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis.
Aim: To compare the efficacy and safety of alectinib with other ALK inhibitors in treating patients with metastatic or locally advanced ALK-positive NSCLC.
Methods: A systematic literature review was conducted up to November 2021. Network meta-analyses were performed using the frequentist method (random effects). GRADE evidence profile was conducted.
Results: 13 RCTs were selected. For overall survival, alectinib was found to reduce the risk of death compared with crizotinib. In progression-free survival, alectinib reduced the risk of death or progression compared with crizotinib and ceritinib. Subgroup analysis by brain metastasis at baseline showed the superiority of alectinib over crizotinib and a similar effect compared with second-and third-generation inhibitors. Alectinib showed a good safety profile compared with the other ALK inhibitors.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
